

CITATION REPORT

List of articles citing

Antimicrobial Activity Evaluation of Tebipenem (SPR859), an Orally Available Carbapenem, against a Global Set of Enterobacteriaceae Isolates, Including a Challenge Set of Organisms

DOI: 10.1128/aac.02618-18

Antimicrobial Agents and Chemotherapy, 2019, 63, .

Source: <https://exaly.com/paper-pdf/73539086/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Safety, Pharmacokinetics, and Food Effect of Tebipenem Pivoxil Hydrobromide after Single and Multiple Ascending Oral Doses in Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	11
17	Resistance among urinary tract pathogens collected in Europe during 2018. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 23, 439-444	3.4	5
16	and Characterization of Tebipenem, an Oral Carbapenem. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	14
15	New treatment options for multiresistant gram negatives. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 214-223	5.4	25
14	A rapid, antibiotic susceptibility test for multidrug-resistant, Gram-negative bacterial uropathogens using the biochemical assay, DETECT. <i>Journal of Microbiological Methods</i> , 2021 , 182, 106160	2.8	1
13	Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 1815-1835	6.2	7
12	Tebipenem pivoxil hydrobromide-No PICC, no problem!. <i>Pharmacotherapy</i> , 2021 , 41, 748-761	5.8	3
11	Tebipenem as an oral alternative for the treatment of typhoid caused by XDR Salmonella Typhi. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 3197-3200	5.1	2
10	The repurposing of Tebipenem pivoxil as alternative therapy for severe gastrointestinal infections caused by extensively drug resistant spp.. <i>ELife</i> , 2022 , 11,	8.9	2
9	Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.. <i>New England Journal of Medicine</i> , 2022 , 386, 1327-1338	59.2	5
8	Pharmacokinetics of Oral Tebipenem Pivoxil Hydrobromide in Subjects with Various Degrees of Renal Impairment.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0240721	5.9	3
7	Evaluation of Tebipenem Hydrolysis by β Lactamases Prevalent in Complicated Urinary Tract Infections.. <i>Antimicrobial Agents and Chemotherapy</i> , 2022 , e0239621	5.9	1
6	The Class A β Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States. <i>Antibiotics</i> , 2022 , 11, 674	4.9	0
5	Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects. <i>Antimicrobial Agents and Chemotherapy</i> ,	5.9	1
4	Determining the in vitro susceptibility of tebipenem, an oral carbapenem, against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolated from bloodstream infections. 2022 , 4,		0
3	Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding.		0
2	Pharmacokinetics and soft-tissue distribution of tebipenem pivoxil hydrobromide using microdialysis: a study in healthy subjects and patients with diabetic foot infections. 2022 , 78, 296-301		0

- 1 Evaluation of Oral Tebipenem as a Step-Down Therapy following Intravenous Ertapenem against Extended-Spectrum β -Lactamase-Producing *Escherichia coli* in a Hollow-Fiber In Vitro Infection Model.

o